HeyJaredDominick DiSabatino
- Indexed articles, last 90 days
- 3
- Latest publication
- Sep 30, 2026
- Outlet visibility, for natlawreview.com
- Top 1M sites
- Earliest in this view
- Aug 6, 2026
Latest articles
FDA Opens Applications for New Pilot to Shorten Drug Approval Times: What Sponsors Need to Know (opens the original)
Read excerpt
Earlier this month, FDA opened applications for a new Expedited Investigational New Drug (IND) Pilot Program (the “Program”), an initiative launched under HHS Operation TrialBlazer[i] that aims to shorten the path from IND-enabling activities to first-in-human (FIH) trials while preserving FDA’s existing safety and scientific review standards. For sponsors racing to get novel candidates into trials, this pilot may offer a different approach: a rolling, collaborative IND review process built arou
Enhanced FDA-SEC Collaboration: How Life Sciences Companies Think About Disclosure, Insider Trading, and Prediction Markets (opens the original)
Read excerpt
On August 31, 2026, the U.S. Securities and Exchange Commission (SEC) and Food and Drug Administration (FDA) signed a Memorandum of Understanding (the “MOU”)[1] to “establish a framework to support the parties’ respective regulatory and enforcement responsibilities and otherwise enhance cooperation.” On its face, the document is not earth-shattering—six pages of information-sharing protocols, points-of-contact designations, and FOIA-referral procedures. But read against the backdrop of prior bio
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides (opens the original)
Read excerpt
In our recent update on peptide regulation, we noted that the FDA is only one layer of the compliance picture. For any company with exposure to multi-state compounding or telehealth operations — whether as an operator, a brand manufacturer monitoring the competitive landscape, or an investor — a jurisdiction-by-jurisdiction breakdown of state requirements is essential. This post maps how states are currently regulating the compounding of GLP-1 receptor agonists (semaglutide and tirzepatide chief
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1M sites
For natlawreview.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.